Genetics and prevention: A new look at high-density lipoprotein cholesterol

Cardiology in Review

Volumn 10, Issue 1, 2002, Pages 61-71

  Genest Jr , Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cardiovascular risk factors; Cholesterol; Epidemiology; Genetics; High density lipoproteins

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID;

APOPTOSIS; BILE ACID SYNTHESIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; GENE MUTATION; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID COMPOSITION; LONGEVITY; MOLECULAR SIZE; PROTEIN CONTENT; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TANGIER DISEASE; THROMBOCYTE FUNCTION; THROMBOSIS; VASOMOTOR REFLEX;

EID: 0036159289     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200201000-00011     Document Type: Review

References (51)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III)
2. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
3. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Executive summary
4. Coronary heart disease: Reducing the risk: A worldwide view
5. High-density lipoprotein: Multipotent effects on cells of the vasculature
6. High-density lipoproteins and endothelial function
7. Plasma lipids and lipoproteins and cardiovascular diseases
8. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
9. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae
10. The class B, type I scavenger receptor promotes the selective uptake of high density cholesterol ethers into caveolae
11. Intracellular cholesterol transport
12. Intracellular cholesterol transport
13. Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes
14. Cell cholesterol efflux: Integration of old and new observations provides new insights
15. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
16. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: The PROCAM experience and pathophysiological implications for reverse cholesterol transport
17. HDL-cholesterol as a marker of coronary heart disease risk: The Quebec cardiovascular study
18. Lipoprotein cholesterol, apolipoproteins A-I and B, and lipoprotein(a) in men with premature coronary artery disease
19. High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport
20. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol
21. Coronary events with lipid-lowering therapy: The AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study
22. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study
23. Familial lipoprotein disorders in patients with premature coronary artery disease
24. Familial hypoalphalipoproteinemia in premature coronary artery disease
25. HDL levels and coronary artery disease in heterozygotes for ABCA1 mutations are predicted by cholesterol efflux levels and influenced by age
26. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
27. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
28. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study
29. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol
30. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
31. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians
32. Genetics of lipoprotein disorders
33. Triglycerides and coronary heart disease: Implications of recent clinical trials
34. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): Questions, quandaries, and paradoxes
35. Lipoprotein phenotype and insulin resistance in familial combined hyperlipidemia
36. Familial combined hyperlipoproteinemia: Experts panel position on diagnostic criteria for clinical practice
37. Lack of association of the apo AI-CIII-AIV gene XmnI and SstI polymorphism and of the LPL gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects
38. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels
39. High density lipoprotein and coronary heart disease: Insights from mutations leading to low high density lipoprotein
40. High density lipoproteins and reverse cholesterol transport: Lessons from mutations
41. Apolipoprotein A-I: Structure-function relationship
42. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris
43. The molecular pathology of lecithin: Cholesterol acyltransferase (LCAT) deficiency syndromes
44. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein
45. Familial lipoprotein lipase deficiency in infancy: Clinical, biochemical, and molecular study
46. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men
47. Tangier disease
48. Mutations in the ATP binding cassette (ABC1) transporter gene in Tangier disease and familial HDL deficiency
49. Familial HDL deficiency with defective cholesterol efflux is caused by mutations in cholesterol efflux regulatory protein (CERP/ABC1)
50. Tangier disease and ABCA1